Home > Boards > US Listed > Biotechs > Jupiter Neurosciences Inc (JUNS)
Followed By 756
Posts 50921
Boards Moderated 15
Alias Born 12/12/2004

Wednesday, February 02, 2022 9:45:31 AM

Re: None

Post# of 3
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Recent JUNS News

Mru Patel Appointed Non-Executive Director of Axis Technologies Group, Inc. AXTG Aug 5, 2022 9:00 AM

HealthLynked to Premier "Forever: The End of Aging" Medical Documentary atCMX CinéBistro Theater in Naples, Florida on August 28th HLYK Aug 5, 2022 8:00 AM

Progressive Care Announces Shareholder Conference Call and Business Update on August 11, 2022 RXMD Aug 5, 2022 7:15 AM

IGEN announces Net Profit for Second Quarter 2022 IGEN Aug 5, 2022 7:08 AM

Kaya Holdings to Seek Licenses for First Ever State Legal Psilocybin Manufacturing and Facilitation Service Centers in Oregon KAYS Aug 4, 2022 12:44 PM

American Rebel Holdings Completes Acquisition of Champion Safe Company, Solidifying A Leading Position in Safe Industry AREBW Aug 4, 2022 10:27 AM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc), Summarizes Its Second Quarter of 2022 Results, Including a 588% Revenue Increase Over the Same Period in 2021 ILUS Aug 4, 2022 10:19 AM

New Intranet- and Cloud-based Monitoring and Management Interface Enhances ResGreen's BotWay Software RGGI Aug 3, 2022 10:53 AM

Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics TOMDF Aug 3, 2022 9:48 AM

EV TECHNOLOGY GROUP ANNOUNCES AGREEMENT TO ACQUIRE UP TO 100% OF FABLINK GROUP, SPEARHEADING FUTURE GLOBAL GROWTH EVTG Aug 3, 2022 9:39 AM

PSYC Corp's Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive Month PSYC Aug 3, 2022 8:30 AM

Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange SIGY Aug 3, 2022 7:07 AM

SmallCapsDaily: Mill City Ventures Outperforms in the Specialty Finance Space MCVT Aug 2, 2022 11:27 AM

Rainmaker Worldwide Inc. Announces Joint Development Agreement with Miranda Water Treatment Systems RAKR Aug 2, 2022 9:15 AM

HealthLynked Announces Significant Upgrades to its Healthcare Network HLYK Aug 2, 2022 8:00 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y